Cargando…
Frequent KIT mutations in skin lesions of patients with BRAF wild-type Langerhans cell histiocytosis
Langerhans cell histiocytosis (LCH) is characterized by mutations of the RAS-RAF-MAPK signaling pathway. We analyzed MAP2K1, NRAS and KIT mutation incidence in skin lesions of BRAF wild-type (wt) LCH patients. We evaluated the occurrence of MAP2K1, NRAS and KIT mutations in seven LCH and one indeter...
Autores principales: | Tóth, Béla, Kiss, Norbert, Hársing, Judit, Kárpáti, Sarolta, Csomor, Judit, Bödör, Csaba, Tímár, József, Rásó, Erzsébet |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581584/ https://www.ncbi.nlm.nih.gov/pubmed/32372223 http://dx.doi.org/10.1007/s00428-020-02820-w |
Ejemplares similares
-
The Driverless Triple-Wild-Type (BRAF, RAS, KIT) Cutaneous Melanoma: Whole Genome Sequencing Discoveries
por: Pipek, Orsolya, et al.
Publicado: (2023) -
Effective BRAF inhibitor vemurafenib therapy in a 2-year-old patient with sequentially diagnosed Langerhans cell histiocytosis and Erdheim–Chester disease
por: Váradi, Zsófia, et al.
Publicado: (2017) -
New somatic BRAF splicing mutation in Langerhans cell histiocytosis
por: Héritier, Sébastien, et al.
Publicado: (2017) -
BRAF V600E-Positive Congenital Multisite Langerhans Cell Histiocytosis
por: Prada Avella, Maria Camila, et al.
Publicado: (2020) -
Langerhans Cell Histiocytosis, Non-Langerhans histiocytosis and concurrent Papillary Thyroid Carcinoma with BRAF V600E mutations: A case report and literature review
por: Wake, Laura, et al.
Publicado: (2019)